Search Results for "data"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for data. Results 1061 to 1070 of 1100 total matches.
Booster Doses of COVID-19 Vaccines
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021 (Issue 1638)
recipients versus 8 in the placebo group. This data
analysis was performed in June 2021, before the
Delta ...
The FDA has expanded the Emergency Use Authorizations
(EUAs) for the mRNA-based COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty) and
Moderna (Spikevax) and the adenovirus-based vaccine
manufactured by Johnson & Johnson/Janssen to
include administration of a booster dose in select
populations after primary immunization with either the
same COVID-19 vaccine or a different one.
Drugs for Head Lice
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
. It has been effective in
small studies,18,19 but more data are needed. Treatment
of individual patients ...
Pediculosis capitis (head lice infestations) occur in
all age groups, but especially in elementary school
children. In most cases, transmission occurs by
head-to-head contact. Pharmacologic treatment is
recommended for persons with live lice or eggs (nits)
within 1 cm of the scalp. Topical pediculicides should
be tried first. Oral therapy is occasionally required for
refractory infestations.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):89-92 doi:10.58347/tml.2024.1704a | Show Introduction Hide Introduction
Lebrikizumab (Ebglyss) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
with
prior exacerbations and elevated eosinophil levels,14
but high-quality data are lacking.
ADVERSE ...
The FDA has approved lebrikizumab-lbkz (Ebglyss –
Lilly), a subcutaneously injected interleukin (IL)-13
antagonist, for treatment of moderate to severe
atopic dermatitis that has not been or cannot be
adequately treated with topical therapy in patients ≥12
years old (weight ≥40 kg). Lebrikizumab is the third
subcutaneously injected human IgG4 monoclonal
antibody to be approved in the US for this indication.
Tralokinumab (Adbry), another IL-13 antagonist, is
also approved for use in patients ≥12 years old, and
dupilumab (Dupixent), an IL-4 and IL-13 inhibitor, is
approved for...
Med Lett Drugs Ther. 2024 Nov 11;66(1715):179-81 doi:10.58347/tml.2024.1715b | Show Introduction Hide Introduction
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
S. pneumoniae (levofloxacin or moxifloxacin) is
recommended pending culture results.16 Although clinical
data ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Antithrombotic Drugs
The Medical Letter on Drugs and Therapeutics • Oct 27, 2014 (Issue 1454)
– Iprivask (Marathon) No data 15 mg SC q12h10 3600.0011
Factor Xa Inhibitors
Fondaparinux4 – generic 5-10 ...
Antiplatelet drugs are the drugs of choice for
prevention and treatment of arterial thrombosis.
Anticoagulants are the drugs of choice for prevention
and treatment of venous thromboembolism and for
prevention of cardioembolic events in patients with
atrial fibrillation.
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
; without cholestyramine,
leflunomide can remain detectable in serum for
up to 2 years. No data ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024 (Issue 1693)
thereafter. Data on the use of
DOACs in patients who weigh >120 kg or have a BMI
>35 kg/m2 are limited ...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8 doi:10.58347/tml.2024.1693a | Show Introduction Hide Introduction
Transdermal Rotigotine (Neupro) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Aug 27, 2007 (Issue 1268)
mg tabs
1. Cost of 30 days’ treatment with the lowest usual dosage based on the most
recent data ...
Rotigotine (Neupro - Schwarz Pharma), a nonergot dopamine agonist in a transdermal patch formulation, was recently approved by the FDA for treatment of early Parkinson's disease (PD).
Who Should Take Vitamin Supplements?
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
data have become available
on the benefits and risks of taking vitamins.
VITAMIN E — Vitamin E ...
Many patients ask their healthcare providers whether
they should take vitamins. Since the last Medical Letter
article on this subject, more data have become available
on the benefits and risks of taking vitamins.
Suflave — A Low-Volume Colonoscopy Preparation
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023 (Issue 1685)
with
magnesium.
PREGNANCY AND LACTATION — No data are available
on the use of Suflave in pregnant or lactating ...
The FDA has approved Suflave (Sebela/Braintree), a
low-volume polyethylene glycol (PEG)- and sulfate-based
product for cleansing of the colon prior to
colonoscopy in adults. Other oral colonoscopy
preparations available in the US are listed in
Table 2. Suflave is marketed as tasting better than
other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51 doi:10.58347/tml.2023.1685b | Show Introduction Hide Introduction